Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin J Edelman

Showing results (81-90 of 186) with videos related to

Pageof 19
Sort By:
Cancer|December 24, 2003
Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinomaPrimo N Lara, Frederick J Meyers, Lisa Y Law, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancerCharles M Rudin, Mark Kozloff, Philip C Hoffman, et al.
Cancer|April 10, 2004
Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urotheliumRobert Dreicer, Judith Manola, Bruce J Roth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2008
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trialsPrimo N Lara, Mary W Redman, Karen Kelly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
KML001 cytotoxic activity is associated with its binding to telomeric sequences and telomere erosion in prostate cancer cellsPornima Phatak, Fangping Dai, Melody Butler, et al.
Plos One|October 17, 2012
CDC25A(Q110del): a novel cell division cycle 25A isoform aberrantly expressed in non-small cell lung cancerRania H Younis, Wei Cao, Ruxian Lin, et al.
Advances in Therapy|August 15, 2019
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid TumorsSanjeevani Arora, Rodion Velichinskii, Randy W Lesh, et al.
Lung Cancer (Amsterdam, Netherlands)|January 19, 2008
Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancerBenjamin B Bridges, Leno Thomas, Petr F Hausner, et al.
Cancer Chemotherapy and Pharmacology|May 9, 2003
Clinical and pharmacologic study of tributyrin: an oral butyrate prodrugMartin J Edelman, Kenneth Bauer, Shyam Khanwani, et al.
Human Pathology|July 19, 2014
GP88 (progranulin): a novel tissue and circulating biomarker for non-small cell lung carcinomaMartin J Edelman, Josephine Feliciano, Binbin Yue, et al.
Pageof 19

Showing results (81-90 of 186) with videos related to

Sort By:
Pageof 19
Cancer|December 24, 2003
Platinum-free combination chemotherapy in patients with advanced or metastatic transitional cell carcinomaPrimo N Lara, Frederick J Meyers, Lisa Y Law, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancerCharles M Rudin, Mark Kozloff, Philip C Hoffman, et al.
Cancer|April 10, 2004
Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urotheliumRobert Dreicer, Judith Manola, Bruce J Roth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 19, 2008
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trialsPrimo N Lara, Mary W Redman, Karen Kelly, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2008
KML001 cytotoxic activity is associated with its binding to telomeric sequences and telomere erosion in prostate cancer cellsPornima Phatak, Fangping Dai, Melody Butler, et al.
Plos One|October 17, 2012
CDC25A(Q110del): a novel cell division cycle 25A isoform aberrantly expressed in non-small cell lung cancerRania H Younis, Wei Cao, Ruxian Lin, et al.
Advances in Therapy|August 15, 2019
Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid TumorsSanjeevani Arora, Rodion Velichinskii, Randy W Lesh, et al.
Lung Cancer (Amsterdam, Netherlands)|January 19, 2008
Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancerBenjamin B Bridges, Leno Thomas, Petr F Hausner, et al.
Cancer Chemotherapy and Pharmacology|May 9, 2003
Clinical and pharmacologic study of tributyrin: an oral butyrate prodrugMartin J Edelman, Kenneth Bauer, Shyam Khanwani, et al.
Human Pathology|July 19, 2014
GP88 (progranulin): a novel tissue and circulating biomarker for non-small cell lung carcinomaMartin J Edelman, Josephine Feliciano, Binbin Yue, et al.
Pageof 19